Relapsed or refractory diffuse large B-cell lymphoma

This study tests whether giving additional antibody drugs (mosunetuzumab or glofitamab plus obinutuzumab) after CAR-T cell therapy can improve outcomes for people with relapsed or refractory large B-cell lymphoma. About 23 participants will receive the combination to see if it le…

Researchers are testing an experimental drug called epcoritamab in adults with diffuse large B-cell lymphoma or classic follicular lymphoma that has come back or stopped responding to earlier treatments. The trial gives the drug as an injection under the skin in increasing doses,…

This early-stage trial tests an investigational drug called ABBV-319 in about 154 adults with certain B-cell cancers (diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The study has two…

This phase 3 trial tests whether adding brentuximab vedotin to two standard drugs (lenalidomide and rituximab) helps people with diffuse large B-cell lymphoma that has returned or not improved after at least two prior treatments. About 239 participants will receive either the add…

This study tests an experimental oral drug, CC-99282, in people with non-Hodgkin lymphoma that has come back or stopped responding to treatment. The drug is given alone or with other lymphoma medicines. The main goals are to check safety and find the best dose, while also seeing …

This study tests an experimental drug called brincidofovir in people with lymphoma (a type of blood cancer) that has returned or not improved after standard treatments. The trial has two parts: first, finding a safe dose in up to 18 people with various lymphomas, then testing tha…

This study tests a modified intravenous dosing schedule of tafasitamab combined with oral lenalidomide in 53 adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for a stem cell transplant. The main goal is to evaluate safety and how the drug move…

This study aimed to test the drug selinexor combined with other treatments for people with a type of blood cancer called diffuse large B-cell lymphoma that had come back or stopped responding to therapy. The trial was planned in two phases to first find the safest dose and then c…

This study tracks 40 patients with aggressive B-cell lymphoma who have received CAR-T cell therapy. Researchers take a blood sample 7 days after treatment to look for leftover tumor DNA. The goal is to see if they can report results within 3 weeks, giving doctors a head start to …